Agilent Technologies (A) has entered into a marketing partnership with Applied Biosystems, a division of Life Technologies Corporation (LIFE). The subject matter of the agreement is Agilent’s SureSelect system, a research tool to be used for re-sequencing specific regions of interest in the genome. The product has been optimized for the SOLiDU system, a next-generation advanced genomic analysis-sequencing platform. Life Technologies Corporation supplies genotyping tools that facilitate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis. The agreement is a positive for Agilent’s Bio Analytic Measurement (BAM) segment, given Life’s market position and experience. We believe it indicates that the recession-driven weakness could be coming to an end and expect the announcement of other marketing initiatives in the next few months. The BAM segment generated $496 million in revenue in the last quarter, which was flattish in comparison ...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

DrStockPick.com Watch List!

My Picks for Thursday September 24, 2009, are:

**************************************************************

RHT, Red Hat Inc.

RHT is the leader in enterprise Linux and is the most recognized open source brand in the world. Solutions include Red Hat Enterprise Linux, JBoss Enterprise middleware, and a broad range of management and services: consulting, 24×7 support, Red Hat Network. RHT’s global training program operates worldwide and features RHCE, the global standard Linux certification.

**RHT’s second-quarter net income rose to $28.9 million, or 15 cents a share, up from net income of $21.1 million, or 10 cents per share in

...

Orchid Cellmark Inc. (ORCH) is a leading provider of DNA testing services for forensic, human identity and agricultural applications in the U.S. and the U.K.Through its facility in the U.K., Orchid conducted genotyping services under the U.K. government's project to help British farmers breed sheep with reduced susceptibility to the animal disease scrapie. The company expanded its reach in the U.S. with the acquisition of ReliaGene in October 2007.The company is now leveraging its expertise in DNA testing to enter into new markets like pork traceability, immigration testing and security applications. The company has won a major part of the mega tender in the U.K., which will result in annual revenues of $10 million for the next 3 years.We believe it is the right time to accumulate Orchid stock as we anticipate significant appreciation in the stock price in the near future. ...

Hologic Inc. (HOLX) soared nearly 11% on Friday after the company said the Food and Drug Administration approved two of its molecular tests for the detection of human papillomavirus (HPV), which can cause cervical cancer.

Cervista HPV HR is designed to detect 14 high-risk types of HPV. Also, Cervista HPV 16/18 became the first test to be approved for genotyping of HPV types 16 and 18, which are associated with about 70% of all cervical cancers in the U.S.

Hologic acquired the Cervista tests when it bought Third Wave Technologies last year. The approval of the two tests is expected to boost Hologic's future earnings significantly. Last month, the company had reduced its full-year guidance to $1.10 to $1.15 per share as it did not expect the Cervista tests to be approved so soon.

After losing more than 20% of their value over the last

...

Orchid Cellmark Inc. (ORCH) is a leading provider of DNA testing services for forensic, human identity and agricultural applications in the U.S. and the U.K. The company is also the world's largest provider of "scrapie susceptibility genotyping."The company expanded its reach in the U.S. with the acquisition of ReliaGene in October 2007. The company is now leveraging its expertise in DNA testing to enter into new markets like pork traceability, immigration testing and security applications. Orchid Cellmark has won a major part of the mega-tender in the U.K., which will result in annual revenues of $10 million for the next 3 years. As such, we maintain our Buy rating on the stock with a revised target price of $2.50.Maharathi Basu contributed to this report.Read the full analyst report on ORCH "ORCH" Free Stock Analysis: Buy? ...

deCODE genetics, Inc. (DCGN) is a biopharmaceutical company that uses genetics to develop drugs, diagnostics, and pharmacogenetics for the healthcare industry.

3Q08 revenue of $12 million was less than our estimate of $16 million. As of September 30, 2008, the company had $17.7 million in deferred revenue that will be recognized over future reporting periods. The period-on-period increase in revenue for the third quarter was driven principally by growth in the company's genomic services business, which includes the company's diagnostics, deCODEme(TM) personal genome analysis, and contract genotyping businesses.

Operating loss for the third quarter 2008 was $11.3 million, compared to $22.2 million for the third quarter 2007. Net loss for the quarter ending September 30, 2008 was $17.9 million, compared to $24.2 million for the third quarter 2007. In addition to operating loss, net loss figures for the periods presented include interest expense and, in the 2008 periods, unrealized loss resulting

...

WaferGen Biosystems, Inc. (WGBS.OB), the California-based gene and stem cell research systems developer, announced today the signing of an exclusive distribution agreement with Euroclone S.p.A in Italy. Euroclone will distribute WaferGen’s SmartSlide™ Micro-Incubation System. WaferGen also signed a distributor agreement for SmartSlide with Takeda Rika Kogyo, Co. Ltd., of Japan. Both distributors serve cell biologists and stem cell researchers in the life science markets within their geographic areas.

WaferGen’s SmartSlide Micro-Incubation System is a unique family of integrated fluidics exchange micro-incubation products that work seamlessly with inverted microscopes. This breakthrough technology is enabling cell biology and stem cell researchers to conduct complex time-lapse imaging studies, to grow and work with stem cells and other difficult to cultivate cells. It allows researchers to pursue cutting-edge research topics that are not addressable with existing technology. As an example, the SmartSlide System will allow researchers to precisely control and vary oxygen, carbon dioxide,

...